题名

使用混合藥物Polypill作為心血管疾病的預防策略之評估

并列篇名

Evaluation of the Effectiveness of a "Polypil" as a Strategy for the Prevention of Cardiovascular Disease

DOI

10.6288/TJPH2012-31-03-02

作者

莊筱婷(Hsiao-Ting Juang)；簡國龍(Kuo-Liong Chien)

关键词

藥物 ； Polypill ； 心血管疾病的預防 ； drugs ； Polypill ； cardiovascular disease prevention

期刊名称

台灣公共衛生雜誌

卷期/出版年月

31卷3期（2012 / 06 / 01）

页次

217 - 227

内容语文

繁體中文
中文摘要

雖然利用生活習慣的改變是防治心血管疾病的基石，但是大多數人無法長期有效地持續進行行為矯正，來維持促進心血管健康。因此，利用包含aspirin、降血壓及降血脂藥物的混合藥劑“Polypill”來預防心血管疾病成為一個值得注意的預防策略。目前關於Polypill的藥效及不良反應之臨床試驗結果顯示出，Polypill是預防心血管疾病的良好策略，並且在醫師及病人對於使用Polypill的態度也顯示有一定可行性。然而，對於Polypill藥物中的組成成分、劑量及藥物的效果和安全性仍需更多的研究來評估，而且也需要進一步地研究Polypill是否能降低心血管疾病發病率及在發展中國家的成本效益分析。
英文摘要

The prevention of cardiovascular disease (CVD) is an important component of health promotion. Although behavioral lifestyle change is considered to be the first priority and the basis for several management modalities, many individuals cannot continue behavioral modification effectively for a long period of time. Therefore, a combination of multiple generic drugs, including aspirin, and blood pressure and cholesterol-lowering medications, becomes an appealing approach to CVD prevention. ”Polypill” is a single pill combining several drugs that could reduce cardiovascular risk. Evidence from the results of randomized clinical trials for the efficacy and adverse effects of ”Polypill” have recently become available. The data showed that ”Polypill” may be a good strategy for the prevention of CVD, and the acceptance of ”Polypill” by some primary care physicians and patients appears to be moderate to high; however, additional studies and more systematic evaluations of the optimal component drug dosage, combination formulae, and the efficacy and safety of the ”Polypill” are needed. Further studies are also warranted in order to determine if the ”Polypill” can reduce the incidence of CVD and is cost-effectiveness for developing countries.
主题分类 醫藥衛生 > 預防保健與衛生學
醫藥衛生 > 社會醫學
参考文献
  1. Clinicaltrials.gov. Basic search. Available at: http://clinicaltrials.gov/ct2/search. Accessed November 20, 2011.
  2. 行政院衛生署：98年度單方藥品健保申報排行。http://www.doh.gov.tw/CHT2006/other/ShowCopy.aspx?doc_no=74802&class_no=25。引用2011/11/20。Department of Health, Executive Yuan, R.O.C.(Taiwan). Rank of single-ingredient drugs by claims to National Health Insurance, 2009. Available at: http://www.doh.gov.tw/CHT2006/other/ShowCopy.aspx?doc_no=74802&class_no=25. Accessed November 20,2011. [In Chinese]
  3. 行政院衛生署：民國99年死因結果摘要表。http://www.doh.gov.tw/CHT2006/DisplayStatisticFile.aspx?d=81294&s=1。引用2011/11/20。Department of Health, Executive Yuan, R.O.C.(Taiwan). The summary of cause of death statistics in 2010. Available at:http://www.doh.gov.tw/CHT2006/DisplayStatisticFile.aspx?d=81294&s=1. Accessed November 20, 2011. [In Chinese]
  4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group(2002).Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMA,288,2981-97.
  5. Avorn, J.,Monette, J.,Lacour, A.(1998).Persistence of use of lipid-lowering medications - a cross-national study.JAMA,279,1458-62.
  6. Bangalore, S.,Wild, D.,Parkar, S.,Kukin, M.,Messerli, F. H.(2008).Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis.J Am Coll Cardiol,52,1062-72.
  7. Berry, T. M.,Prosser, T. R.,Wilson, K.,Castro, M.(2011).Asthma friendly pharmacies:a model to improve communication and collaboration among pharmacists, patients, and healthcare providers.J Urban Health,88,113-25.
  8. Black, H. R.(2004).Calcium channel blockers in the treatment of hypertension and prevention of cardiovascular disease:results from major clinical trials.Clin Cornerstone,6,53-66.
  9. Combination Pharmacotherapy and Public Health Research Working Group(2005).Combination pharmacotherapy for cardiovascular disease.Ann Intern Med,143,593-9.
  10. Connor, J.,Rafter, N.,Rodgers, A.(2004).Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review.Bull World Health Organ,82,935-9.
  11. Dabhadkar, K.C.,Kulshreshtha, A.,Ali, M. K.,Narayan, K. M.(2011).Prospects for a cardiovascular disease prevention polypill.Annu Rev Public Health,32,23-38.
  12. De Berardis, G.,Sacco, M.,Strippoli, G. F.(2009).Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials.BMJ,339,b4531.
  13. Ebrahim, S.,Taylor, F.,Ward, K.,Beswick, A.,Burke, M.,Davey, Smith G.(2011).Multiple risk factor interventions for primary prevention of coronary heart disease.Cochrane Database Syst Rev,1,CD001561.
  14. Foody, J. M.,Joyce, A. T.,Jeffers, B. W.,Liu, L. Z.,Benner, J. S.(2011).A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in hypertensive patients without prior cardiovascular disease.Am J Ther,18,110-6.
  15. Gaziano, T. A.(2005).Cardiovascular disease in the developing world and its cost-effective management.Circulation,112,2547-53.
  16. Gaziano, T. A.,Opie, L. H.,Weinstein, M. C.(2006).Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis.Lancet,368,679-86.
  17. Gharpure, K.,Thawani, V.,Sontakke, S.,Chaudhari, K.,Bankar, M.,Diwe, R.(2011).Effect of information, education and communication intervention on awareness about rational pharmacy practice in pharmacy students.Indian J Pharmacol,43,381-4.
  18. Girvin, B.,McDermott, B. J.,Johnston, G. D.(1999).A comparison of enalapril 20 mg once daily versus 10 mg twice daily in terms of blood pressure lowering and patient compliance.J Hypertens,17,1627-31.
  19. Green, L. W.(2005).Prospects and possible pitfalls of a preventive polypill: confessions of a health promotion convert.Eur J Clin Nutr,59,S4-9.
  20. Holt, S.(2009).New Zealand general practitioners' opinions of the polypill concept.N Z Med J,122,116-7.
  21. Huang, E. S.,Strate, L. L.,Ho, W. W.,Lee, S. S.,Chan, A. T.(2011).Long-term use of aspirin and the risk of gastrointestinal bleeding.Am J Med,124,426-33.
  22. Kernan, W. N.,Launer, L. J.,Goldstein, L. B.(2010).What is the future of stroke prevention?: debate: polypill versus personalized risk factor modification.Stroke,41,S35-8.
  23. Law, M. R.,Wald, N. J.,Morris, J. K.,Jordan, R. E.(2003).Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.BMJ,326,1427.
  24. Law, M. R.,Wald, N. J.,Rudnicka, A. R.(2003).Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.BMJ,326,1423.
  25. Liu, H.,Patel, A.,Brown, A.(2010).Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non indigenous people at high cardiovascular risk.BMC Public Health,10,458.
  26. Lonn, E.,Bosch, J.,Teo, K. K.,Pais, P.,Xavier, D.,Yusuf, S.(2010).The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions.Circulation,122,2078-88.
  27. Malekzadeh, F.,Marshall, T.,Pourshams, A.(2010).A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.Int J Clin Pract,64,1220-7.
  28. Minder, C. M.,Blaha, M. J.,Horne, A.,Michos, E. D.,Kaul, S.,Blumenthal, R. S.(2012).Evidence-based use of statins for primary prevention of cardiovascular disease.Am J Med,125,440-6.
  29. Monane, M.,Bohn, R. L.,Gurwitz, J. H.,Glynn, R. J.,Levin, R.,Avorn, J.(1997).The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly.Am J Hypertens,10,697-704.
  30. Mulrow, C.,Kussmaul, W.(2005).The middle-aged and older American: wrong prototype for a preventive polypill?.Ann Intern Med,142,467-8.
  31. Muntner, P.,Mann, D.,Wildman, R. P.,Shimbo, D.,Fuster, V.,Woodward, M.(2011).Projected impact of polypill use among US adults: medication use, cardiovascular risk reduction, and side effects.Am Heart J,161,719-25.
  32. Patel, A.,Shah, T.,Shah, G.(2010).Preservation of bioavailability of ingredients and lack of drugdrug interactions in a novel five-ingredient polypill (polycap): a five-arm phase i crossover trial in healthy volunteers.Am J Cardiovasc Drugs,10,95-103.
  33. Piette, J. D.,Heisler, M.,Wagner, T. H.(2004).Cost-related medication underuse among chronically ill adults: the treatments people forgo, how often, and who is at risk.Am J Public Health,94,1782-7.
  34. Reardon, S.(2011).Public health. Experts debate polypill: a single pill for global health.Science,333,1813.
  35. Reddy, K. S.(2007).The preventive polypill-much promise, insufficient evidence.N Engl J Med,356,212.
  36. Rishi, R. K.(2011).Polypill-friend or foe?.Indian J Pharmacol,43,361-2.
  37. Rodgers, A.,Patel, A.,Berwanger, O.(2011).An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.PLoS One,6,e19857.
  38. Sanz, G.,Fuster, V.(2011).Polypill and global cardiovascular health strategies.Semin Thorac Cardiovasc Surg,23,24-9.
  39. Selak, V.,Elley, C. R.,Crengle, S.(2011).Improving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care.Contemp Clin Trials,32,909-15.
  40. Sleight, P.,Pouleur, H.,Zannad, F.(2006).Benefits, challenges, and registerability of the polypill.Eur Heart J,27,1651-6.
  41. Soliman, E. Z.,Mendis, S.,Dissanayake, W. P.(2011).A polypill for primary prevention of cardiovascular disease: a feasibility study of the WHO.Trials,12,3.
  42. Viera, A. J.(2011).The polypill to prevent cardiovascular disease:physicians' perspectives.Curr Opin Cardiol,26,438-42.
  43. Viera, A. J.,Sheridan, S. L.,Edwards, T.,Soliman, E. Z.,Harris, R.,Furberg, C. D.(2011).Acceptance of a polypill approach to prevent cardiovascular disease among a sample of U.S. physicians.Prev Med,52,10-5.
  44. Vos, T.,Carter, R.,Barendregt, J.(2010).,Australia:University of Queensland, Brisbane and Deakin University.
  45. Wald, D. S.,Wald, N. J.(2012).Implementation of a simple agebased strategy in the prevention of cardiovascular disease: the polypill approach.J Eval Clin Pract,18,612-5.
  46. Wald, N. J.,Law, M. R.(2003).A strategy to reduce cardiovascular disease by more than 80%.BMJ,326,1419.
  47. WHO(2002).Secondary Prevention of Non-Communicable Disease in Low and Middle Income Countries Through Community-Based and Health Service.Geneva:WHO.
  48. Yusuf, S.(2002).Two decades of progress in preventing vascular disease.Lancet,360,2-3.
  49. Yusuf, S.,Pais, P.,Afzal, R.(2009).Effects of a polypill (polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.Lancet,373,1341-51.
  50. Zhou, Y. H.,Tang, J. Y.,Wu, M. J.(2011).Effect of folic acid supplementation on cardiovascular outcomes: a systematic review and meta-analysis.PLoS One,6,e25142.
print cancel